

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/70, 1/21, C07K 14/705, 16/28, C12Q 1/68, A61K 38/17		A1	(11) International Publication Number: WO 99/10491
			(43) International Publication Date: 4 March 1999 (04.03.99)
(21) International Application Number: PCT/US98/17690			(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).
(22) International Filing Date: 26 August 1998 (26.08.98)			
(30) Priority Data: 08/919,624 28 August 1997 (28.08.97) US			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/919,624 (CIP) Filed on 28 August 1997 (28.08.97)			Published With international search report.
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). SHAH, Purvi [IN/US]; 1608 Queen Charlotte Drive #5, Sunnyvale, CA 94087 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US).			
(54) Title: NEW HUMAN G-PROTEIN COUPLED RECEPTOR			
(57) Abstract The invention provides a human G-protein coupled receptor (GReCH) and polynucleotides which identify and encode GReCH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GReCH.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NEW HUMAN G-PROTEIN COUPLED RECEPTOR

TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of a new human G-protein coupled receptor and to the use of these sequences in the diagnosis, prevention, and treatment of endocrine, neurological, and cardiovascular disorders.

BACKGROUND OF THE INVENTION

10 G-protein coupled receptors (GPCRs) are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which span the plasma membrane and form a bundle of antiparallel alpha helices. The transmembrane domains account for structural and functional features of the receptor. In most cases, the bundle of helices forms a binding pocket; however, when the binding site must accommodate more
15 bulky molecules, the extracellular N-terminal segment or one or more of the three extracellular loops participate in binding and in subsequent induction of conformational change in intracellular portions of the receptor. The activated receptor, in turn, interacts with an intracellular heterotrimeric G-protein complex which mediates further intracellular signaling activities, generally interaction with guanine nucleotide binding (G) proteins and the
20 production of second messengers such as cyclic AMP (cAMP), phospholipase C, inositol triphosphate or ion channel proteins (Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6:180-190).

The amino-terminus of the GPCR is extracellular, of variable length and often glycosylated, while the carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops of the GPCR alternate with intracellular loops and link the transmembrane
25 domains. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. GPCRs range in size from under 400 to over 1000 amino acids (Coughlin, S.R. (1994) Curr. Opin. Cell Biol. 6:191-197).

GPCRs respond to a diverse array of ligands including lipid analogs, amino acids and their derivatives, peptides, cytokines, and specialized stimuli such as light, taste, and odor.
30 GPCRs function in physiological processes including vision (the rhodopsins), smell (the olfactory receptors), neurotransmission (muscarinic acetylcholine, dopamine, and adrenergic receptors), and hormonal response (luteinizing hormone and thyroid-stimulating hormone

receptors).

GPCR mutations, both of the loss-of-function and of the activating variety, have been associated with numerous human diseases (Coughlin, supra). For instance, retinitis pigmentosa may arise from either loss-of-function or activating mutations in the rhodopsin gene. Somatic activating mutations in the thyrotropin receptor cause hyperfunctioning thyroid adenomas (Parma, J. et al. (1993) *Nature* 365:649-651). Parma et al. suggest that certain G-protein-coupled receptors susceptible to constitutive activation may behave as proto-oncogenes.

Neuropeptide Y (NPY), pancreatic polypeptide (PP), and peptide YY (PYY) are structurally related peptides found in higher vertebrates. NPY is produced in the central and peripheral nervous systems. NPY plays a role in the stimulation of food intake, anxiety, facilitation of learning and memory, and regulation of the neuroendocrine and cardiovascular systems. NPY also stimulates vascular smooth muscle contraction, modulates hormone secretion, and has been implicated in the pathophysiology of hypertension, congestive heart failure, affective disorders and appetite regulation (Watson, S. and S. Arkinstall (1994) *The G-Protein Linked Receptor Facts Book*, Academic Press, San Diego CA, pp. 194-198). PP is produced in endocrine cells in the pancreas and inhibits pancreatic secretion, gall bladder contraction, and gut motility. PYY is produced in endocrine cells of the pancreas and large intestine. PYY has actions similar to those of PP, and in addition redistributes blood flow in gut vessels. Both PP and PYY are released into the circulation in response to food intake. These structurally related peptides accomplish their varied biological functions through interaction with distinct GPCR subtypes. Several receptor subtypes have been defined by their ability to bind NPY, PYY, PP, and derivatives of these peptides. At least five distinct receptor subtypes have been characterized to date (Weinberg, D.H. et al. (1996) *J. Biol. Chem.* 271:16435-16438).

Cholecystokinin (CCK) is a bioactive peptide which is present throughout the digestive tract, and is also found in smooth muscle tissues such as bladder and uterus, in secretory glands such as exocrine pancreas, and in the brain. The major physiological actions of CCK are gall bladder contraction, pancreatic enzyme secretion, and regulation of secretion/absorption in the gastrointestinal tract. CCK receptors are GPCRs found in peripheral tissues including pancreas, stomach, intestine and gall bladder, and in limited amounts in the brain. CCK receptors mediate pancreatic acinar secretion and gallbladder

contraction (De Weerth, A. et al. (1993) Am. J. Physiol. 265:G1116-G1121). The CCK-A receptor has been implicated in the pathogenesis of schizophrenia, Parkinson's disease, drug addiction and feeding disorders (Watson and Arkinstall, supra, pp. 89-95).

The discovery of a new human G-protein coupled receptor and the polynucleotides encoding it satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention and treatment of endocrine, neurological, and cardiovascular disorders.

SUMMARY OF THE INVENTION

The invention features a substantially purified polypeptide, human G-protein coupled receptor (GRecH), having the amino acid sequence shown in SEQ ID NO:1, or fragments thereof.

The invention further provides an isolated and substantially purified polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof and a composition comprising said polynucleotide sequence. The invention also provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the amino acid sequence SEQ ID NO:1, or fragments of said polynucleotide sequence. The invention further provides a polynucleotide sequence comprising the complement of the polynucleotide sequence encoding the amino acid sequence of SEQ ID NO:1, or fragments or variants of said polynucleotide sequence.

The invention also provides an isolated and purified sequence comprising SEQ ID NO:2 or variants thereof. In addition, the invention provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:2. The invention also provides a polynucleotide sequence comprising the complement of SEQ ID NO:2, or fragments or variants thereof.

The present invention further provides an expression vector containing at least a fragment of any of the claimed polynucleotide sequences. In yet another aspect, the expression vector containing the polynucleotide sequence is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment thereof, the method comprising the steps of: a) culturing the host cell containing an expression vector containing at least a fragment of the polynucleotide sequence encoding GRcH under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified GRecH having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

The invention also provides a purified antagonist of the polypeptide of SEQ ID NO:1.

5 In one aspect the invention provides a purified antibody which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

Still further, the invention provides a purified agonist of the polypeptide of SEQ ID NO:1.

10 The invention also provides a method for treating or preventing an endocrine disorder comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising purified GRecH.

The invention also provides a method for treating or preventing a neurological disorder comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising purified GRecH.

15 The invention also provides a method for treating or preventing a cardiovascular disorder comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising purified GRecH.

The invention also provides a method for detecting a polynucleotide which encodes GRecH in a biological sample comprising the steps of: a) hybridizing the complement of the polynucleotide sequence which encodes SEQ ID NO:1 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and b) detecting the hybridization complex, wherein the presence of the complex correlates with the presence of a polynucleotide encoding GRecH in the biological sample. In one aspect the nucleic acid material of the biological sample is amplified by the polymerase chain reaction prior to hybridization.

20

25

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A, 1B, 1C, 1D, 1E, and 1F show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of GRecH. The alignment was produced using MacDNASIS PRO™ software (Hitachi Software Engineering Co. Ltd. San Bruno, CA).

30

Figures 2A, 2B, and 2C show the amino acid sequence identity alignments among GRecH (282414; SEQ ID NO:1), CCK-A receptor from guinea pig (GI 544724; SEQ ID

5 Figures 3A, 3B, and 3C show the amino acid sequence similarity alignments among
GReCH (282414; SEQ ID NO:1), CCK-A receptor from guinea pig (GI 544724; SEQ ID
NO:3) and neuropeptide Y receptor from mouse (GI 1378004; SEQ ID NO:4). Aligned
amino acids with chemically similar functional groups are boxed. The alignment was
produced using the multisequence alignment program of DNASTAR™ software (DNASTAR
10 Inc, Madison WI).

15 **DESCRIPTION OF THE INVENTION**

It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a host cell” includes a plurality of such host cells, reference to the “antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

5

methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

5 DEFINITIONS

GRecH, as used herein, refers to the amino acid sequences of substantially purified GRecH obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

10 The term "agonist", as used herein, refers to a molecule which, when bound to GRecH, increases or prolongs the duration of the effect of GRecH. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of GRecH.

An "allele" or "allelic sequence", as used herein, is an alternative form of the gene encoding GRecH. Alleles may result from at least one mutation in the nucleic acid sequence
15 and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes
20 may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding GRecH as used herein include those with deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent GRecH. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide
25 probe of the polynucleotide encoding GRecH, and improper or unexpected hybridization to alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GRecH. The encoded protein may also be "altered" and contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GRecH. Deliberate amino acid substitutions may be made on the
30 basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological or immunological activity of GRecH is retained. For example, negatively charged amino acids may include aspartic acid

and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, serine and threonine, and phenylalanine and tyrosine.

5 "Amino acid sequence" as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragment thereof, and to naturally occurring or synthetic molecules. Fragments of GRecH are preferably about 5 to about 15 amino acids in length and retain the biological activity or the immunological activity of GRecH. Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule,
10 amino acid sequence, and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

 "Amplification" as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR
15 Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

 The term "antagonist" as used herein, refers to a molecule which, when bound to GRecH, decreases the amount or the duration of the effect of the biological or immunological activity of GRecH. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules which decrease the effect of GRecH.

20 As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind GRecH polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal can be derived from the translation of RNA or
25 synthesized chemically and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin, keyhole limpet hemocyanin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

 The term "antigenic determinant", as used herein, refers to that fragment of a
30 molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-

dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense", as used herein, refers to any composition containing nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules include peptide nucleic acids and may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and block either transcription or translation. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic GReCH, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A". Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands and in the design and use of PNA molecules.

A "composition comprising a given polynucleotide sequence" as used herein refers broadly to any composition containing the given polynucleotide sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GReCH (SEQ ID NO:1) or fragments thereof (e.g., SEQ ID NO:2 and fragments thereof) may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a

carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS) and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus", as used herein, refers to a nucleic acid sequence which has been
5 resequenced to resolve uncalled bases, has been extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly (e.g., GELVIEW™ Fragment Assembly system, GCG, Madison, WI). Some sequences have been both extended and assembled to produce the consensus sequence .

10 The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern analysis is indicative of the presence of mRNA encoding GRecH in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

15 A "deletion", as used herein, refers to a change in the amino acid or nucleotide sequence and results in the absence of one or more amino acid residues or nucleotides.

The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding or complementary to GRecH or the encoded GRecH. Such modifications include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic
20 acid derivative encodes a polypeptide which retains the biological or immunological function of the natural molecule. A derivative polypeptide is one which is modified by glycosylation, pegylation, or any similar process which retains the biological or immunological function of the polypeptide from which it was derived.

The term "homology", as used herein, refers to a degree of complementarity. There
25 may be partial homology or complete homology (i.e., identity). A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution
30 hybridization and the like) under conditions of low stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of low stringency. This is not

to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity). In the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

Human artificial chromosomes (HACs) are linear microchromosomes which may contain DNA sequences of 10K to 10M in size and contain all of the elements required for stable mitotic chromosome segregation and maintenance (Harrington, J.J. et al. (1997) Nat Genet. 15:345-355).

The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

The term "hybridization", as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_{0t} or R_{0t} analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, as compared to the naturally occurring molecule.

"Microarray" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.

The term "modulate", as used herein, refers to a change in the activity of GReCH. For example, modulation may cause an increase or a decrease in protein activity, binding

characteristics, or any other biological, functional or immunological properties of GRecH.

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand.

5 "Fragments" are those nucleic acid sequences which are greater than 60 nucleotides in length, and most preferably includes fragments that are at least 100 nucleotides or at least 1000 nucleotides, and at least 10,000 nucleotides in length.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to about 60 nucleotides, preferably about 15 to 30 nucleotides, and more
10 preferably about 20 to 25 nucleotides, which can be used in PCR amplification or a hybridization assay, or a microarray. As used herein, oligonucleotide is substantially equivalent to the terms "amplimers", "primers", "oligomers", and "probes", as commonly defined in the art.

"Peptide nucleic acid", PNA as used herein, refers to an antisense molecule or
15 anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues which ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in the cell where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

20 The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from five amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length GRecH and fragments thereof.

25 The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding GRecH, or fragments thereof, or GRecH itself may comprise a bodily fluid, extract from a cell, chromosome, organelle, or membrane isolated from a cell, a cell, genomic DNA, RNA, or cDNA (in solution or bound to a solid support, a tissue, a tissue print, and the like).

30 The terms "specific binding" or "specifically binding", as used herein, refers to that interaction between a protein or peptide and an agonist, an antibody and an antagonist. The interaction is dependent upon the presence of a particular structure (i.e., the antigenic

determinant or epitope) of the protein recognized by the binding molecule. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

5 The terms "stringent conditions" or "stringency", as used herein, refer to the conditions for hybridization as defined by the nucleic acid, salt, and temperature. These conditions are well known in the art and may be altered in order to identify or detect identical or related polynucleotide sequences. Numerous equivalent conditions comprising either low or high stringency depend on factors such as the length and nature of the sequence (DNA, RNA, base
10 composition), nature of the target (DNA, RNA, base composition), milieu (in solution or immobilized on a solid substrate), concentration of salts and other components (e.g., formamide, dextran sulfate and/or polyethylene glycol), and temperature of the reactions (within a range from about 5°C below the melting temperature of the probe to about 20°C to 25°C below the melting temperature). One or more factors be may be varied to generate
15 conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

 The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components
20 with which they are naturally associated.

 A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

 "Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using
25 various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the
30 inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

A "variant" of GReCH, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

THE INVENTION

The invention is based on the discovery of a new human G-protein coupled receptor (hereinafter referred to as "GReCH"), the polynucleotides encoding GReCH, and the use of these compositions for the diagnosis, prevention, or treatment of neurological, endocrine, and cardiovascular disorders.

Nucleic acids encoding the GReCH of the present invention were first identified in Incyte Clone 282414 from the cardiac muscle cDNA library CARDNOT01 using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 282414 (CARDNOT01) and 306020 (HEARNOT01).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figs. 1A-1F. GReCH is 433 amino acids in length and, as shown in Figs. 2A-2C and Figs. 3A-3C, has chemical and structural homology with the GPCRs CCK-A receptor from guinea pig (GI 544724; SEQ ID NO:3) and neuropeptide Y receptor from mouse (GI 1378004; SEQ ID NO:4). In particular, GReCH and guinea pig CCK-A receptor share 37% "amino acid sequence similarity" and 19% amino acid sequence identity; GReCH and mouse neuropeptide Y receptor share 35% similarity and 19% identity. "Amino acid sequence similarity" means that the sequences have chemically similar functional groups as defined in Karlin, S. et al. (1985; Proc Natl. Acad. Sci. USA 82:8597-8601). As illustrated by Figs. 4A and 4B, GReCH and guinea pig CCK-A receptor have similar hydrophobicity plots. GReCH contains seven potential transmembrane domains which are characteristic of GPCRs. The approximate locations of these transmembrane (TM)

domains are: Y36-M68 (TM1); I73-L107 (TM2); N110-L138 (TM3); M154-S183 (TM4); Y210-I242 (TM5); M314-S342 (TM6); and L348-F369 (TM7). GRecH contains four potential N-linked glycosylation sites, three of which, at residues N16, N192 and N333, are predicted to reside on the extracellular side of the membrane. GRecH also contains eight
5 potential phosphorylation sites, six of which, at residues S144, T259, T264, S388, S404, and T415, are predicted to reside on the intracellular side of the membrane. Northern analysis shows the expression of this sequence in various libraries, including endocrine tissue (adrenal gland), smooth muscle (uterus), cardiac muscle (fetal and adult heart), and neuronal tissue (fetal and infant brain).

10 The invention also encompasses GRecH variants. A preferred GRecH variant is one having at least 80%, and more preferably at least 90%, amino acid sequence identity to the GRecH amino acid sequence (SEQ ID NO:1) and which retains at least one biological, immunological or other functional characteristic or activity of GRecH. A most preferred GRecH variant is one having at least 95% amino acid sequence identity to SEQ ID NO:1.

15 The invention also encompasses polynucleotides which encode GRecH. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of GRecH can be used to produce recombinant molecules which express GRecH. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID NO:2 as shown in Figs. 1A-1F.

20 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding GRecH, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices.

25 These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring GRecH, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GRecH and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring GRecH under
30 appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GRecH or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs

in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GRecH and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or fragments thereof, which encode GRecH and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GRecH or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

Methods for DNA sequencing which are well known and generally available in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

The nucleic acid sequences encoding GRecH may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round

of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers
5 based on a known region (Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186). The primers may be designed using commercially available software such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to
10 generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR
amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119). In this
15 method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested
20 primers, and PromoterFinder™ libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly
25 primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In
30 particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled devise camera. Output/light

intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GRecH may be used in recombinant DNA molecules to direct expression of GRecH, fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express GRecH.

As will be understood by those of skill in the art, it may be advantageous to produce GRecH-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GRecH encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GRecH may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of GRecH activity, it may be useful to encode a chimeric GRecH protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the GRecH encoding sequence and the heterologous protein sequence, so that GRecH may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding GRecH may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of GRecH, or a fragment thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of GRecH, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active GRecH, the nucleotide sequences encoding GRecH or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GRecH and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GRecH. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus

expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The invention is not limited by the host cell employed.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding GReCH, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for GReCH. For example, when large quantities of GReCH are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding GReCH may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released

from the GST moiety at will.

In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

5 In cases where plant expression vectors are used, the expression of sequences encoding GReCH may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock
10 promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in
15 McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.

An insect system may also be used to express GReCH. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences
20 encoding GReCH may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of GReCH will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which GReCH may be expressed (Engelhard, E.K. et al. (1994)
25 *Proc. Nat. Acad. Sci.* 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GReCH may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the
30 viral genome may be used to obtain a viable virus which is capable of expressing GReCH in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be

used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6 to 10M are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GRecH. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding GRecH, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; Bethesda, MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express GRecH may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable

marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

5 Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk⁻ or apt⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for
10 example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to
15 utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable
20 protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding GRecH is inserted within a marker gene sequence, transformed cells
25 containing sequences encoding GRecH can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GRecH under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding GRecH and
30 express GRecH may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip

based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding GRecH can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding GRecH. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding GRecH to detect transformants containing DNA or RNA encoding GRecH.

A variety of protocols for detecting and measuring the expression of GRecH, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GRecH is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GRecH include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GRecH, or any fragments thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GRecH may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in

the art, expression vectors containing polynucleotides which encode GRecH may be designed to contain signal sequences which direct secretion of GRecH through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding GRecH to nucleotide sequence encoding a polypeptide domain which will facilitate

5 purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker

10 sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and GRecH may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing GRecH and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMAC (immobilized metal ion affinity

15 chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281) while the enterokinase cleavage site provides a means for purifying GRecH from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of GRecH may be produced by

20 direct peptide synthesis using solid-phase techniques Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of GRecH may be chemically synthesized separately and combined using chemical methods to produce the full length

25 molecule.

THERAPEUTICS

Chemical and structural homology exists among GRecH and CCK-A receptor from guinea pig (GI 544724) and neuropeptide Y receptor from mouse (GI 1378004). In addition,

30 GRecH is expressed in endocrine tissue, smooth muscle, cardiac muscle, and neuronal tissue. Therefore, GRecH appears to be involved in intracellular signaling activities, and to play a role in endocrine, neurological, and cardiovascular disorders.

Therefore, in one embodiment, GReCH or a fragment or derivative thereof may be administered to a subject to treat or prevent an endocrine disorder. Such disorders include, but are not limited to, Addison's disease, carcinoid syndrome, Cushing's disease, diabetes insipidus, diabetes mellitus, hyperaldosteronism, hyper- and hypoglycemia, goiter, Grave's disease, multiple endocrine neoplasia syndromes, pheochromocytoma, polyendocrine deficiency syndromes, and thyroiditis.

In another embodiment, a vector capable of expressing GReCH, or a fragment or a derivative thereof, may also be administered to a subject to treat or prevent an endocrine disorder including, but not limited to, those described above.

In still another embodiment, an agonist which modulates the activity of GReCH may also be administered to a subject to treat or prevent an endocrine disorder including, but not limited to, those described above.

In another embodiment, GReCH or a fragment or derivative thereof may be administered to a subject to treat or prevent a neurological disorder. Such disorders include, but are not limited to, akathisia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, cerebral neoplasms, dementia, depression, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, multiple sclerosis, neurofibromatosis, Parkinson's disease, paranoid psychoses, schizophrenia, and Tourette's disorder, and disorders of the sympathetic nervous system including angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and pheochromocytoma.

In another embodiment, a vector capable of expressing GReCH, or a fragment or a derivative thereof, may also be administered to a subject to treat or prevent a neurological disorder including, but not limited to, those described above.

In still another embodiment, an agonist which modulates the activity of GReCH may also be administered to a subject to treat or prevent a neurological disorder including, but not limited to, those described above.

In another embodiment, GReCH or a fragment or derivative thereof may be administered to a subject to treat or prevent a cardiovascular disorder. Such disorders include, but are not limited to, angina, arrhythmias, anaphylactic shock, arteriosclerosis, cardiomyopathy, cardiovascular shock, coronary artery disease, endocarditis, hypertension, myocardial infarction, myocardial ischemia, pericarditis, rheumatic heart disease, and septic

shock.

In another embodiment, a vector capable of expressing GRecH, or a fragment or a derivative thereof, may also be administered to a subject to treat a cardiovascular disorder including, but not limited to, those described above.

5 In still another embodiment, an agonist which modulates the activity of GRecH may also be administered to a subject to treat a cardiovascular disorder including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences or vectors of the invention may be administered in combination
10 with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of
15 each agent, thus reducing the potential for adverse side effects.

An antagonist of GRecH may be produced using methods which are generally known in the art. In particular, purified GRecH may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GRecH.

Antibodies to GRecH may be generated using methods that are well known in the art.
20 Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice,
25 humans, and others, may be immunized by injection with GRecH or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole
30 limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies

to GRecH have an amino acid sequence consisting of at least five amino acids and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of GRecH amino acids
5 may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to GRecH may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma
10 technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with
15 appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; Takeda, S. et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GRecH-specific single chain antibodies. Antibodies with related
20 specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:11120-3).

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding
25 reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for GRecH may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments
30 which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al.

(1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GRecH and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GRecH epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

In another embodiment of the invention, the polynucleotides encoding GRecH, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding GRecH may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding GRecH. Thus, complementary molecules or fragments may be used to modulate GRecH activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding GRecH.

Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence which is complementary to the polynucleotides of the gene encoding GRecH. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

Genes encoding GRecH can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes GRecH. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or

regulatory regions of the gene encoding GRecH (signal sequence, promoters, enhancers, and introns). Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GRecH.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding GRecH. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections or polycationic amino polymers (Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-66; incorporated herein by reference) may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of GRecH, antibodies to GRecH, mimetics, agonists, antagonists, or inhibitors of GRecH. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which

facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

5 Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

10 Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other
15 plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

20 Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

25 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable
30 liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's

solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of GReCH, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful

doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GRecH or fragments thereof, antibodies of GRecH, agonists, antagonists or inhibitors of GRecH, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.

Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind GRecH may be used for the diagnosis of conditions or diseases characterized by expression of GRecH, or in assays to

monitor patients being treated with GRecH, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for GRecH include methods which utilize the antibody and a label to detect GRecH in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring GRecH are known in the art and provide a basis for diagnosing altered or abnormal levels of GRecH expression. Normal or standard values for GRecH expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to GRecH under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric, means. Quantities of GRecH expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding GRecH may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of GRecH may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of GRecH, and to monitor regulation of GRecH levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GRecH or closely related molecules, may be used to identify nucleic acid sequences which encode GRecH. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding GRecH, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the GRecH encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring GRecH.

Means for producing specific hybridization probes for DNAs encoding GRecH include the cloning of nucleic acid sequences encoding GRecH or GRecH derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as ³²P or ³⁵S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GRecH may be used for the diagnosis of conditions or disorders which are associated with expression of GRecH. Examples of such conditions or disorders include endocrine disorders such as Addison's disease, carcinoid syndrome, Cushing's disease, diabetes insipidus, diabetes mellitus, hyperaldosteronism, hyper- and hypoglycemia, goiter, Grave's disease, multiple endocrine neoplasia syndromes, pheochromocytoma, polyendocrine deficiency syndromes, and thyroiditis; neurological disorders such as akathisia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, cerebral neoplasms, dementia, depression, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, multiple sclerosis, neurofibromatosis, Parkinson's disease, paranoid psychoses, schizophrenia, and Tourette's disorder, and disorders of the sympathetic nervous system including angina, anaphylactic shock, arrhythmias, asthma, cardiovascular shock, Cushing's syndrome, hypertension, hypoglycemia, myocardial infarction, migraine, and pheochromocytoma; and cardiovascular disorders such as angina, arrhythmias, anaphylactic shock, arteriosclerosis, cardiomyopathy, cardiovascular shock, coronary artery disease, endocarditis, hypertension, myocardial infarction, myocardial ischemia, pericarditis, rheumatic heart disease, and septic shock. The polynucleotide sequences encoding GRecH may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dipstick, pin, ELISA assays or microarrays utilizing fluids or tissues from patient biopsies to detect altered GRecH

expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GRecH may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding GRecH may be labeled by standard methods, and
5 added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the
10 presence of altered levels of nucleotide sequences encoding GRecH in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of
15 GRecH, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes GRecH, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount
20 of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays
25 may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in
30 biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to

employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding GRecH may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'→3') and another with antisense (3'←5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of GRecH include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, an oligonucleotide derived from any of the polynucleotide sequences described herein may be used as a target in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously (to produce a transcript image), and to identify genetic variants, mutations and polymorphisms. This information will be useful in determining gene function, understanding the genetic basis of disease, diagnosing disease, and in developing and monitoring the activity of therapeutic agents (Heller, R. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-55).

In one embodiment, the microarray is prepared and used according to the methods described in PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference.

The microarray is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25

nucleotides in length. For a certain type of microarray, it may be preferable to use oligonucleotides which are only 7-10 nucleotides in length. The microarray may contain oligonucleotides which cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray may be oligonucleotides that are specific to a gene or genes of interest in which at least a fragment of the sequence is known or that are specific to one or more unidentified cDNAs which are common to a particular cell type, developmental or disease state.

In order to produce oligonucleotides to a known sequence for a microarray, the gene of interest is examined using a computer algorithm which starts at the 5' or more preferably at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray. The "pairs" will be identical, except for one nucleotide which preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray, the RNA or DNA from a

biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray so that the probe sequences hybridize to complementary oligonucleotides of the microarray.

5 Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray. The biological samples may be obtained
10 from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies on the sequences, mutations, variants, or polymorphisms among samples.

15 In another embodiment of the invention, the nucleic acid sequences which encode GRecH may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome or to artificial chromosome constructions, such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs),
20 bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) *Blood Rev.* 7:127-134, and Trask, B.J. (1991) *Trends Genet.* 7:149-154.

Fluorescent in situ hybridization (FISH as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be
25 correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in various scientific journals or at Online Mendelian Inheritance in Man (OMIM). Correlation between the location of the gene encoding GRecH on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease.

30 The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques

such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to
5 chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or
10 regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, GRecH, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of
15 a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between GRecH and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput
20 screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to GRecH large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with GRecH, or fragments thereof, and washed. Bound GRecH is then detected by methods well known in the art.

25 Purified GRecH can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GRecH specifically compete with a test compound
30 for binding GRecH. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GRecH.

In additional embodiments, the nucleotide sequences which encode GRecH may be

used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not
5 included for the purpose of limiting the invention.

EXAMPLES

I CARDNOT01 cDNA Library Construction

The CARDNOT01 library was constructed using RNA isolated from the normal
10 cardiac muscle of a 65-year-old Caucasian male, who died from a self-inflicted gunshot wound. The tissue was obtained from the Keystone Skin Bank, International Institute for the Advancement of Medicine (Exton, PA). The tissue was flash frozen, ground in a mortar and pestle, and lysed immediately in buffer containing guanidinium isothiocyanate. Lysis was followed by several phenol chloroform extractions and ethanol precipitation. Poly(A⁺) RNA
15 was isolated using biotinylated oligo d(T) primer and streptavidin coupled to a paramagnetic particle (Promega Corp.) and sent to Stratagene. Stratagene prepared the cDNA library using oligo d(T) priming. Synthetic oligonucleotides were ligated onto the cDNA molecules enabling them to be inserted into the Uni-ZAP™ vector system (Stratagene). The quality of the cDNA library was screened using cDNA probes, and then, the pBluescript® phagemid
20 (Stratagene) was excised and was subsequently transformed into host cells (SOLR®, Stratagene).

II Isolation and Sequencing of cDNA Clones

The phagemid forms of individual cDNA clones were obtained by the in vivo excision
25 process, and phagemid DNA released from the cells, purified, and used to reinfect fresh host cells (SOLR®, Stratagene) where double stranded DNA was produced. Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit (Catalog #26173, QIAGEN, Inc., Chatsworth, CA). The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog
30 #22711, GIBCO BRL, Gaithersburg, MD) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the

plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C.

The cDNAs were sequenced by the method of Sanger et al. (1975; J. Mol. Biol. 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with
5 Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA Sequencing Systems; and the reading frame was determined.

III Homology Searching of cDNA Clones and Their Deduced Proteins

The nucleotide sequences of the Sequence Listing or amino acid sequences deduced
10 from them were used as query sequences against databases such as GenBank, SwissProt, BLOCKS, and Pima II. These databases which contain previously identified and annotated sequences were searched for regions of homology (similarity) using BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul et al. (1990) J. Mol. Biol. 215:403-410).

15 BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal or plant) origin. Other algorithms such as the one described in Smith R.F. and T.F. Smith (1992; Protein Engineering 5:35-51),
20 incorporated herein by reference, can be used when dealing with primary sequence patterns and secondary structure gap penalties. As disclosed in this application, the sequences have lengths of at least 49 nucleotides, and no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

The BLAST approach, as detailed in Karlin, S. and S.F. Altschul (1993; Proc. Nat.
25 Acad. Sci. 90:5873-7) and incorporated herein by reference, searches for matches between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. In this application, threshold was set at 10^{-25} for nucleotides and 10^{-14} for peptides.

30 Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and mammalian sequences (mam), and deduced amino acid sequences from the same clones are searched against GenBank functional protein databases,

mammalian (mamp), vertebrate (vrtp) and eukaryote (eukp), for homology. The relevant database for a particular match were reported as a GLxxx±p (where xxx is pri, rod, etc and if present, p = peptide).

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., supra).

Analogous computer techniques using BLAST (Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul, S.F. et al. (1990) J. Mol. Evol. 215:403-410) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding GReCH occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of GReCH Encoding Polynucleotides

The nucleic acid sequence of the Incyte Clone 282414 was used to design oligonucleotide primers for extending a partial nucleotide sequence to full length. One

primer was synthesized to initiate extension in the antisense direction, and the other was synthesized to extend sequence in the sense direction. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be about 22 to about 30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures of about 68° to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (Gibco/BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

Step 1	94° C for 1 min (initial denaturation)
Step 2	65° C for 1 min
Step 3	68° C for 6 min
Step 4	94° C for 15 sec
Step 5	65° C for 1 min
Step 6	68° C for 7 min
Step 7	Repeat step 4-6 for 15 additional cycles
Step 8	94° C for 15 sec
Step 9	65° C for 1 min
Step 10	68° C for 7:15 min
Step 11	Repeat step 8-10 for 12 cycles
Step 12	72° C for 8 min
Step 13	4° C (and holding)

A 5-10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQuick™ (QIAGEN Inc., Chatsworth, CA), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture

was incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB)-agar (Sambrook et al., supra)

5 containing 2x Carb. The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample was transferred into a PCR array.

10 For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

Step 1	94° C for 60 sec
15 Step 2	94° C for 20 sec
Step 3	55° C for 30 sec
Step 4	72° C for 90 sec
Step 5	Repeat steps 2-4 for an additional 29 cycles
Step 6	72° C for 180 sec
20 Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

25 In like manner, the nucleotide sequence of SEQ ID NO:2 is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

VI Labeling and Use of Individual Hybridization Probes

30 Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont

35

NEN[®], Boston, MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN[®]).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR[™] film (Kodak, Rochester, NY) is exposed to the blots in a Phosphorimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

VII Microarrays

To produce oligonucleotides for a microarray, the nucleotide sequence described herein is examined using a computer algorithm which starts at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that would interfere with hybridization. The algorithm identifies 20 sequence-specific oligonucleotides of 20 nucleotides in length (20-mers). A matched set of oligonucleotides is created in which one nucleotide in the center of each sequence is altered. This process is repeated for each gene in the microarray, and double sets of twenty 20 mers are synthesized and arranged on the surface of the silicon chip using a light-directed chemical process (Chee, M. et al., PCT/WO95/11995, incorporated herein by reference).

In the alternative, a chemical coupling procedure and an ink jet device are used to synthesize oligomers on the surface of a substrate (Baldeschweiler, J.D. et al., PCT/WO95/25116, incorporated herein by reference). In another alternative, a "gridded" array analogous to a dot (or slot) blot is used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array may be produced by hand or using available materials and machines and contain grids of 8 dots, 24 dots, 96 dots, 384 dots, 1536 dots or 6144 dots. After hybridization, the microarray is washed to remove nonhybridized

probes, and a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the micro-array.

5 VIII Complementary Polynucleotides

Sequence complementary to the GRecH-encoding sequence, or any part thereof, is used to decrease or inhibit expression of naturally occurring GRecH. Although use of oligonucleotides comprising from about 15 to about 30 base-pairs is described, essentially the same procedure is used with smaller or larger sequence fragments. Appropriate
10 oligonucleotides are designed using Oligo 4.06 software and the coding sequence of GRecH, SEQ ID NO:1. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GRecH-encoding transcript.

15

IX Expression of GRecH

Expression of GRecH is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector is also used to express GRecH in *E. coli*. Upstream of the cloning site, this vector contains a
20 promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard
25 methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein.

X Demonstration of GRecH Activity

A procedure for testing GRecH activity utilizes the baculovirus expression system in
30 Sf9 insect cells. Sf9 cells are capable of both the co-translational and post-translational processing events which facilitate receptor and G protein subunit interaction (Taussig, R. et al. (1994) Methods Enzymol. 238:95-108). Infection of the Sf9 cells with recombinant

baculovirus containing GRecH results in cells with GRecH properly expressed and positioned in the cell membrane. Agonists and antagonists which specifically bind the receptor can be identified and measured using techniques well known in the art.

5 **XI Production of GRecH Specific Antibodies**

GRecH that is substantially purified using PAGE electrophoresis (Sambrook, *supra*), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a
10 corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (*supra*), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole
15 limpet hemocyanin (KLH; Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio iodinated, goat anti-
20 rabbit IgG.

XII Purification of Naturally Occurring GRecH Using Specific Antibodies

Naturally occurring or recombinant GRecH is substantially purified by immunoaffinity chromatography using antibodies specific for GRecH. An immunoaffinity
25 column is constructed by covalently coupling GRecH antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GRecH is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GRecH (e.g., high ionic
30 strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GRecH binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GRecH is collected.

XIII Identification of Molecules Which Interact with GRecH

GRecH or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed
5 in the wells of a multi-well plate are incubated with the labeled GRecH, washed and any wells with labeled GRecH complex are assayed. Data obtained using different concentrations of GRecH are used to calculate values for the number, affinity, and association of GRecH with the candidate molecules.

All publications and patents mentioned in the above specification are herein
10 incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed
15 should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

What is claimed is:

1. A substantially purified human G-protein coupled receptor comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.

5

2. A substantially purified variant of human G-protein coupled receptor having at least 90% amino acid identity to SEQ ID NO:1 and which retains at least one functional characteristic of human G-protein coupled receptor.

10

3. An isolated and purified polynucleotide sequence encoding the human G-protein coupled receptor of claim 1 or fragments or variants of said polynucleotide sequence.

4. A composition comprising the polynucleotide sequence of claim 3.

15

5. A polynucleotide sequence which hybridizes to the polynucleotide sequence of claim 3.

6. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 3 or fragments or variants thereof.

20

7. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or fragments or variants thereof.

8. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 7.

25

9. An expression vector containing at least a fragment of the polynucleotide sequence of claim 3.

30

10. A host cell containing the vector of claim 9.

11. A method for producing a polypeptide comprising the amino acid sequence of

SEQ ID NO:1, or a fragment thereof, the method comprising the steps of:

- a) culturing the host cell of claim 10 under conditions suitable for the expression of the polypeptide; and
- b) recovering the polypeptide from the host cell culture.

5

12. A pharmaceutical composition comprising a substantially purified human G-protein coupled receptor having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

10

13. A purified antibody which specifically binds to the polypeptide of claim 1.

14. A purified agonist of the polypeptide of claim 1.

15. A purified antagonist of the polypeptide of claim 1.

15

16. A method for treating an endocrine disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 12.

20

17. A method for treating a neurological disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 12.

18. A method for treating a cardiovascular disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 12.

25

19. A method for detecting a polynucleotide which encodes human G-protein coupled receptor in a biological sample comprising the steps of:

30

- a) hybridizing the polynucleotide of claim 6 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
- b) detecting said hybridization complex, wherein the presence of said

complex correlates with the presence of a polynucleotide encoding human G-protein coupled receptor in said biological sample.

20. The method of claim 19 wherein the nucleic acid material is amplified by the
5 polymerase chain reaction prior to hybridization.

1/14

9	18	27	36	45	54
T GAC CCT AAT AAA GCA TGT AGC TGA AGT ATT' GGA GAG AAA ACG AAA GAA TTC					
63	72	81	90	99	108
CTC CAA GAC ATG AAA TAA AAC ACA GCT ACT TCA CTG TTG TCA GGG AAA AAA ACC					
117	126	135	144	153	162
AAC TGC TCC AAA AGA ATG TGT TTT TCT CCC ATT CTG GAA ATC AAC ATG CAG TCT					
	M C F S P I L E I N M Q S				
171	180	189	198	207	216
GAA TCT AAC ATT ACA GTG CGA GAT GAC ATT GAT GAC ATC AAC ACC AAT ATG TAC					
E S N I T V R D D I D D I N T N M Y					
225	234	243	252	261	270
CAA CCA CTA TCA TAT CCG TTA AGC TTT CAA GTG TCT CTC ACC GGA TTT CTT ATG					
Q P L S Y P L S F Q V S L T G F L M					
279	288	297	306	315	324
TTA GAA ATT TTT TTT GGA CTT GGC AGC AAC CTC ACT GTA TTG GTA CTT TAC TGC					
L E I F F G L G S N L T V L V L Y C					
333	342	351	360	369	378
ATG AAA TCC AAC TTA ATC AAC TCT GTC AGT AAC ATT ATT ACA ATG AAT CTT CAT					
M K S N L I N S V S N I I T M N L H					

FIG. 1A

2/14

387	396	405	414	423	432
GTA CTT GAT GTA ATA ATT TGT GTG GGA TGT ATT CCT CTA ACT ATA GTT ATC CTT					
V L D V I I C V G C I P L T I V I L					
441	450	459	468	477	486
CTG CTT TCA CTG GAG AGT AAC ACT GCT CTC ATT TGC TGT TTC CAT GAG GCT TGT					
L L S L E S N T A L I C C F H E A C					
495	504	513	522	531	540
GTA TCT TTT GCA AGT GTC TCA ACA GCA ATC AAC GTT TTT GCT ATC ACT TTG GAC					
V S F A S V S T A I N V F A I T L D					
549	558	567	576	585	594
AGA TAT GAC ATC TCT GTA AAA CCT GCA AAC CGA ATT CTG ACA ATG GGC AGA GCT					
R Y D I S V K P A N R I L T M G R A					
603	612	621	630	639	648
GTA ATG TTA ATG ATA TCC ATT TGG ATT TTT TCT TTT TTC TCT TTC CTG ATT CCT					
V M L M I S I S I W I F S F F F L I P					
657	666	675	684	693	702
TTT ATT GAG GTA AAT TTT TTC AGT CTT CAA AGT GGA AAT ACC TGG GAA AAC AAG					
F I E V N F F S L Q S G N T W E N K					
711	720	729	738	747	756
ACA CTT TTA TGT GTC AGT ACA AAT GAA TAC TAC ACT GAA CTG GGA ATG TAT TAT					
T L L C V S T N E Y Y T E L G M Y Y					

FIG. 1B

3/14

765	774	783	792	801	810
CAC CTG TTA GTA CAG ATC CCA ATA TTC TTT ACT GTT GTA ATG TTA ATC					
H L L V Q I P I F F F T V V M L I					
819	828	837	846	855	864
ACA TAC ACC AAA ATA CTT CAG GCT CTT AAT ATT CGA ATA GGC ACA AGA TTT TCA					
T Y T K I L Q A L N I R I G T R F S					
873	882	891	900	909	918
ACA GGG CAG AAG AAG AAA GCA AGA AAG AAA AAG ACA ATT TCT CTA ACC ACA CAA					
T G Q K K K A R K K K T I S L T T Q					
927	936	945	954	963	972
CAT GAG GCT ACA GAC ATG TCA CAA AGC AGT GGT GGG AGA AAT GTA GTC TTT GGT					
H E A T D M S Q S S G G R N V V F G					
981	990	999	1008	1017	1026
GTA AGA ACT TCA GTT TCT GTA ATA ATT GCC CTC CGG CGA GCT GTG AAA CGA CAC					
V R T S V S V I I A L R R A V K R H					
1035	1044	1053	1062	1071	1080
CGT GAA CGA CGA GAA AGA CTA AAG AGA GTC TTC AGG ATG TCT TTA TTG ATT ATT					
R E R R E R L K R V F R M S L L I I					
1089	1098	1107	1116	1125	1134
TCT ACA TTT CTT CTC TGC TGG ACA CCA ATT TCT GTT TTA AAT ACC ACC ATT TTA					
S T F L L C W T P I S V L N T T I L					

FIG. 1C

4/14

1143	1152	1161	1170	1179	1188
TGT TTA GGC CCA AGT GAC CTT TTA GTA AAA TTA AGA TTG TGT TTT TTA GTC ATG					
C L G P S D L L V K L R L C F L V M					
1197	1206	1215	1224	1233	1242
GCT TAT GGA ACA ACT ATA TTT CAC CCT CTA TTA TAT GCA TTC ACT AGA CAA AAA					
A Y G T I F H P L L Y A F T R Q K					
1251	1260	1269	1278	1287	1296
TTT CAA AAG GTC TTG AAA AGT AAA ATG AAA AAG CGA GTT GTT TCT ATA GTA GAA					
F Q K V L K S K M K K R V V S I V E					
1305	1314	1323	1332	1341	1350
GCT GAT CCC CTG CCT AAT AAT GCT GTA ATA CAC AAC TCT TGG ATA GAT CCT AAA					
A D P L P N N A V I H N S W I D P K					
1359	1368	1377	1386	1395	1404
AGA AAC AAA AAA ATT ACC TTT GAA GAT AGT GAA ATA AGA GAA AAA TGT TTA GTG					
R N K K I T F E D S E I R E K C L V					
1413	1422	1431	1440	1449	1458
CCT CAG GTT GTC ACA GAC TAG AGA AAA GTC TCA GTT TCA CCA AAT CCA CAT TCA					
P Q V V T D					
1467	1476	1485	1494	1503	1512
AAT GAG TTT TAA ATT TAA ATT GTA AAA ACT GAT ATT ACT GCC AAA TAT AAG AAA					

FIG. 1D

5/14

1521	1530	1539	1548	1557	1566
AAT ATT TTA AGT ATT GGT TAT GTT GTA AAT TTT CAA TGT GAA TGT CAA TTA GAT					
1575	1584	1593	1602	1611	1620
AGG TCA TAT ATA TTC AAT TTC TTC ATT ACT TAA TGT ATT TGT TGC ATG GCA GTT					
1629	1638	1647	1656	1665	1674
TGT TAA AGT ACT ATC ATG TGT ATA TTT TGT CAA TAT TAT GTC CAA CAG AAA ATA					
1683	1692	1701	1710	1719	1728
TTC ATG TAA GTC ATA TTT TTT AAG GAA TAA ATA CAT AGC CTT AAA ACA GTG TAT					
1737	1746	1755	1764	1773	1782
AAC TTT AAA ATG TAA CTG ACA TAG GTA TCC TTG CTT TAT TTT TTA AGT TAA AAT					
1791	1800	1809	1818	1827	1836
GCA TTG TTT CTA AGC CAC AAA CTA CAG ATA TAT TTA GAT TAC AAC TGG AGT AGC					
1845	1854	1863	1872	1881	1890
ATT TTA ATC TAA AAA CCA AAA TTA TGG GCT CAA AAC AAT CCA GTA TTT TCC ATA					
1899	1908	1917	1926	1935	1944
CCA CTA TGC TAT GTT TCC TGG TAT AGT GTA TTT GCT ATA TTT GAT GCA TCA CAA					
1953	1962	1971	1980	1989	1998
ATA ATT AAG TAC GTA TGA AGC TTT ATT CTT TTA AAT GTA AAA AAT CAT AGA ATT					

FIG. 1E

6/14

2007	2016	2025	2034	2043	2052
TAT CAA AAT TTT AAA ATT AAT GAA CCA AAA AAA CCT CTG TAT ACA CAC CAA AAT					
2061	2070	2079	2088	2097	2106
AGA GAA ACT TTA AAA TTC ATG CTT ACT AGG AAA AAA AAG ATT GAT TTT CTA AGT					
2115	2124	2133	2142	2151	2160
TCA AGG ACA GTA TGC CTA TAA TAT ACA AAT GAA ATG AAA CTA AAG GGA AGG AAG					
2169	2178	2187	2196	2205	2214
AAT ACT AAA ACA CCA GCC TCT TTC TTC CTT CCT CAC TTT GCT TAA GTC TAA GCC					
2223	2232				
AAA TGC TCT GGA TTA ATA TAC TCA CA					

FIG. 1F

7/14

1 M C F S P I L E I N M Q S E S N I T V R 282414
 1 M - - - D V V D S L F V N G S N I T S A GI 544724
 1 M - - - E V L T N Q P T P N K T S G K S GI 1378004

 21 D D I D D I N T N M Y - - - - - 282414
 18 C E L G F E N E T L F C L D R P R P S K GI 544724
 18 - - - - - N N S A F F Y F E S C Q P - - GI 1378004

 32 - - Q P L S Y P L S F Q V S L T G F L M 282414
 38 E W Q P A V Q I L L - - - - Y S L I F L GI 544724
 31 - - - P F L A I L L L L I A Y T V I L I GI 1378004

 50 L E I F F G L G S N L T V L V L Y C M K 282414
 54 L S V L - - - - G N - T L V I T V L I R GI 544724
 48 M G I F - - - - G N L S L I I I I F K K GI 1378004

 70 S N L I N S V S N I I T M N L H V L D V 282414
 69 N K R M R T V T N I F L L S L A V S D L GI 544724
 64 Q R E A Q N V T N I L I A N L S L S D I GI 1378004

 90 I I C V G C I P L T I V I L L L S L E S 282414
 89 M L C L F C M P F N L I P S L L K D F I GI 544724
 84 L V C V M C I P F T V I Y T L M D H W V GI 1378004

 110 N T A L I C C F H E A C V S F A S V S T 282414
 109 F G S A V C - - - K T T T Y F M G T S V GI 544724
 104 F G N T M C - - - K L T S Y V Q S V S V GI 1378004

 130 A I N V F A - - - I T L D R Y D I S V K 282414
 126 S V S T F N L V A I S L E R Y G A I C K GI 544724
 121 S V S I F S L V L I A I E R Y Q L I V N GI 1378004

 147 P A N - - - R I L T M G R A V M L M I S 282414
 146 P L Q S R V W Q T K - S H A L K V I A A GI 544724
 141 P - - - R G W K P R V A H A Y W G I I L GI 1378004

FIG. 2A

8/14

164 I W I F S F F S F L I P - - - F I E V N 282414
 165 T W C L S F - T I M T P Y P I Y S N L V GI 544724
 158 I W L I S L - T L - - S I P L F - - - L GI 1378004

181 F F S L Q S G N T W E N K T L L C V S T 282414
 184 P F T K N N N Q T G N M C R F L - L P N GI 544724
 172 S Y H L T N E P F H N L S - - - - L P T GI 1378004

201 N E Y Y T E L G - - M Y Y H L L V Q I P 282414
 203 D V M Q Q - - - - - T W H T F L L L I GI 544724
 188 D I Y T H Q V A C V E I W P S K L N Q L GI 1378004

219 I F F F T V V V M L I T Y T K I L Q A L 282414
 217 L F L I P G I V M M V A Y G - - L I S L GI 544724
 208 L F - - - - - - - S T S - - L F M L GI 1378004

239 N I R I G T R F S T G Q K K K A R K K K 282414
 235 E L Y Q G I K F D A I Q K K S A K E R K GI 544724
 217 Q Y F V P L G F I L I - - - - - - - - - - GI 1378004

259 T I S L T T - - - - Q H E A T D M S Q S 282414
 255 T S T G S S G P M E D S D G C Y L Q K S GI 544724
 228 - - - - - - - - - - - - - C Y L K I V GI 1378004

275 S G G R N V V F G V R T S V S V I I A L 282414
 275 R H P R K L E L R Q L S P S S S G S N R GI 544724
 234 - - - - - L C L R K - - - - - - - - - - R GI 1378004

295 R R A V K R H R E R R E R L - - - K R V 282414
 295 I N R I - R S S S S T A N L M A K K R V GI 544724
 240 T R Q V D R R K E N K S R L N E N K R V GI 1378004

312 F R M S L L I I S T F L L C W T P I S V 282414
 314 I R M L I V I V V L F F L C W M P - - I GI 544724
 260 N V M L I S I V V T F G A C W L P L N I GI 1378004

FIG. 2B

9/14

332 L N - - - - - T T I L C L G P S 282414
 332 F S A N - A W R A Y D T V S A E R H L S GI 544724
 280 F N V I F D W - - Y H E M L M S C H H D GI 1378004

 343 D L L V K L R L C F L V M A Y G T T I F 282414
 351 G T P I S F I L - - L L - S Y T S S C V GI 544724
 298 - - - L V F V V C H L I - A M V S T C I GI 1378004

 363 H P L L Y A F T R Q K F Q K V L K S K M 282414
 368 N P I I Y C F M N K R F R L G F M A T F GI 544724
 314 N P L F Y G F L N K N F Q K D L M M L I GI 1378004

 383 K K - R V V S I V E A D P L P N N A V I 282414
 388 P - C - C P N P G T P G V R G E M G E E GI 544724
 334 H H C W C G E P Q E S Y E N I A M S T M GI 1378004

 402 H N S W I D P K R N K K I T F E D S E I 282414
 406 E E G R T T G A S L S R Y S Y S H - - - GI 544724
 354 H T D E S K G S - - - - L K L A H - - - GI 1378004

 422 R E K C L V P Q V V T D 282414
 423 - - - - M S T S A P P P GI 544724
 367 - - - - I P T G I GI 1378004

FIG. 2C

10/14

1 M C F S P I L E I N M Q S E S N I T V R 282414
 1 M - - - D V V D S L F V N G S N I T S A GI 544724
 1 M - - - E V L T N Q P T P N K T S G K S GI 1378004

21 D D I D D I N T N M Y - - - - - 282414
 18 C E L G F E N E T L F C L D R P R P S K GI 544724
 18 - - - - - N N S A F F Y F E S C Q P - - GI 1378004

32 - - Q P L S Y P L S F Q V S L T G F L M 282414
 38 E W Q P A V Q I L L - - - - Y S L I F L GI 544724
 31 - - - P F L A I L L L L I A Y T V I L I GI 1378004

50 L E I F F G L G S N L T V L V L Y C M K 282414
 54 L S V L - - - - G N - T L V I T V L I R GI 544724
 48 M G I F - - - - G N L S L I I I I F K K GI 1378004

70 S N L I N S V S N I I T M N L H V L D V 282414
 69 N K R M R T V T N I F L L S L A V S D L GI 544724
 64 Q R E A Q N V T N I L I A N L S L S D I GI 1378004

90 I I C V G C I P L T I V I L L L S L E S 282414
 89 M L C L F C M P F N L I P S L L K D F I GI 544724
 84 L V C V M C I P F T V I Y T L M D H W V GI 1378004

110 N T A L I C C F H E A C V S F A S V S T 282414
 109 F G S A V C - - - K T T T Y F M G T S V GI 544724
 104 F G N T M C - - - K L T S Y V Q S V S V GI 1378004

130 A I N V F A - - - I T L D R Y D I S V K 282414
 126 S V S T F N L V A I S L E R Y G A I C K GI 544724
 121 S V S I F S L V L I A I E R Y Q L I V N GI 1378004

147 P A N - - - R I L T M G R A V M L M I S 282414
 146 P L Q S R V W Q T K - S H A L K V I A A GI 544724
 141 P - - - R G W K P R V A H A Y W G I I L GI 1378004

FIG. 3A

164 I W I F S F F S F L I P - - - F I E V N 282414
 165 T W C L S F - T I M T P Y P I Y S N L V GI 544724
 158 I W L I S L - T L - - S I P L F - - - L GI 1378004

181 F F S L Q S G N T W E N K T L L C V S T 282414
 184 P F T K N N N Q T G N M C R F L - L P N GI 544724
 172 S Y H L T N E P F H N L S - - - - L P T GI 1378004

201 N E Y Y T E L G - - M Y Y H L L V Q I P 282414
 203 D V M Q Q - - - - - T W H T F L L L I GI 544724
 188 D I Y T H Q V A C V E I W P S K L N Q L GI 1378004

219 I F F F T V V V M L I T Y T K I L Q A L 282414
 217 L F L I P G I V M M V A Y G - - L I S L GI 544724
 208 L F - - - - - - - - S T S - - L F M L GI 1378004

239 N I R I G T R F S T G Q K K K A R K K K 282414
 235 E L Y Q G I K F D A I Q K K S A K E R K GI 544724
 217 Q Y F V P L G F I L I - - - - - - - - GI 1378004

259 T I S L T T - - - - Q H E A T D M S Q S 282414
 255 T S T G S S G P M E D S D G C Y L Q K S GI 544724
 228 - - - - - - - - - - C Y L K I V GI 1378004

275 S G G R N V V F G V R T S V S V I I A L 282414
 275 R H P R K L E L R Q L S P S S S G S N R GI 544724
 234 - - - - - L C L R K - - - - - - - - R GI 1378004

295 R R A V K R H R E R R E R L - - - K R V 282414
 295 I N R I - R S S S S T A N L M A K K R V GI 544724
 240 T R Q V D R R K E N K S R L N E N K R V GI 1378004

312 F R M S L L I I S T F L L C W T P I S V 282414
 314 I R M L I V I V V L F F L C W M P - - I GI 544724
 260 N V M L I S I V V T F G A C W L P L N I GI 1378004

FIG. 3B

12/14

332 L N - - - - - T T I L C L G P S 282414
 332 F S A N - A W R A Y D T V S A E R H L S GI 544724
 280 F N V I F D W - - Y H E M L M S C H H D GI 1378004

343 D L L V K L R L C F L V M A Y G T T I F 282414
 351 G T P I S F I L - - L L - S Y T S S C V GI 544724
 298 - - - L V F V V C H L I - A M V S T C I GI 1378004

363 H P L L Y A F T R O K F O K V L K S K M 282414
 368 N P I I Y C F M N K R F R L G F M A T F GI 544724
 314 N P L F Y G F L N K N F O K D L M M L I GI 1378004

383 K K - R V V S I V E A D P L P N N A V I 282414
 388 P - C - C P N P G T P G V R G E M G E E GI 544724
 334 H H C W C G E P Q E S Y E N I A M S T M GI 1378004

402 H N S W I D P K R N K K I T F E D S E I 282414
 406 E E G R T T G A S L S R Y S Y S H - - - GI 544724
 354 H T D E S K G S - - - - L K L A H - - - GI 1378004

422 R E K C L V P Q V V T D 282414
 423 - - - - M S T S A P P P GI 544724
 367 - - - - I P T G I GI 1378004

FIG. 3C

13/14




FIG. 4A

14/14




FIG. 4B

<110> INCYTE PHARMACEUTICALS, INC.

LAL, Preeti

GUEGLER, Karl J.

SHAH, Purvi

CORLEY, Neil C.

<120> NEW HUMAN G-PROTEIN COUPLED RECEPTOR

<130> PF-0377 PCT

<140> To Be Assigned

<141> Herewith

<150> US 08/919,624

<151> 1997-08-28

<160> 4

<170> PERL Program

<210> 1

<211> 433

<212> PRT

<213> Homo sapiens

<220> -

<223> 282414

<400> 1

Met	Cys	Phe	Ser	Pro	Ile	Leu	Glu	Ile	Asn	Met	Gln	Ser	Glu	Ser	
1				5					10					15	
Asn	Ile	Thr	Val	Arg	Asp	Asp	Ile	Asp	Asp	Ile	Asn	Thr	Asn	Met	
				20					25					30	
Tyr	Gln	Pro	Leu	Ser	Tyr	Pro	Leu	Ser	Phe	Gln	Val	Ser	Leu	Thr	
				35					40					45	
Gly	Phe	Leu	Met	Leu	Glu	Ile	Phe	Phe	Gly	Leu	Gly	Ser	Asn	Leu	
				50					55					60	
Thr	Val	Leu	Val	Leu	Tyr	Cys	Met	Lys	Ser	Asn	Leu	Ile	Asn	Ser	
				65					70					75	
Val	Ser	Asn	Ile	Ile	Thr	Met	Asn	Leu	His	Val	Leu	Asp	Val	Ile	
				80					85					90	
Ile	Cys	Val	Gly	Cys	Ile	Pro	Leu	Thr	Ile	Val	Ile	Leu	Leu	Leu	
				95					100					105	
Ser	Leu	Glu	Ser	Asn	Thr	Ala	Leu	Ile	Cys	Cys	Phe	His	Glu	Ala	
				110					115					120	
Cys	Val	Ser	Phe	Ala	Ser	Val	Ser	Thr	Ala	Ile	Asn	Val	Phe	Ala	
				125					130					135	
Ile	Thr	Leu	Asp	Arg	Tyr	Asp	Ile	Ser	Val	Lys	Pro	Ala	Asn	Arg	
				140					145					150	
Ile	Leu	Thr	Met	Gly	Arg	Ala	Val	Met	Leu	Met	Ile	Ser	Ile	Trp	
				155					160					165	
Ile	Phe	Ser	Phe	Phe	Ser	Phe	Leu	Ile	Pro	Phe	Ile	Glu	Val	Asn	
				170					175					180	
Phe	Phe	Ser	Leu	Gln	Ser	Gly	Asn	Thr	Trp	Glu	Asn	Lys	Thr	Leu	
				185					190					195	
Leu	Cys	Val	Ser	Thr	Asn	Glu	Tyr	Tyr	Thr	Glu	Leu	Gly	Met	Tyr	
				200					205					210	
Tyr	His	Leu	Leu	Val	Gln	Ile	Pro	Ile	Phe	Phe	Phe	Thr	Val	Val	
				215					220					225	
Val	Met	Leu	Ile	Thr	Tyr	Thr	Lys	Ile	Leu	Gln	Ala	Leu	Asn	Ile	
				230					235					240	
Arg	Ile	Gly	Thr	Arg	Phe	Ser	Thr	Gly	Gln	Lys	Lys	Lys	Ala	Arg	

				245					250					255
Lys	Lys	Lys	Thr	Ile	Ser	Leu	Thr	Thr	Gln	His	Glu	Ala	Thr	Asp
				260					265					270
Met	Ser	Gln	Ser	Ser	Gly	Gly	Arg	Asn	Val	Val	Phe	Gly	Val	Arg
				275					280					285
Thr	Ser	Val	Ser	Val	Ile	Ile	Ala	Leu	Arg	Arg	Ala	Val	Lys	Arg
				290					295					300
His	Arg	Glu	Arg	Arg	Glu	Arg	Leu	Lys	Arg	Val	Phe	Arg	Met	Ser
				305					310					315
Leu	Leu	Ile	Ile	Ser	Thr	Phe	Leu	Leu	Cys	Trp	Thr	Pro	Ile	Ser
				320					325					330
Val	Leu	Asn	Thr	Thr	Ile	Leu	Cys	Leu	Gly	Pro	Ser	Asp	Leu	Leu
				335					340					345
Val	Lys	Leu	Arg	Leu	Cys	Phe	Leu	Val	Met	Ala	Tyr	Gly	Thr	Thr
				350					355					360
Ile	Phe	His	Pro	Leu	Leu	Tyr	Ala	Phe	Thr	Arg	Gln	Lys	Phe	Gln
				365					370					375
Lys	Val	Leu	Lys	Ser	Lys	Met	Lys	Lys	Arg	Val	Val	Ser	Ile	Val
				380					385					390
Glu	Ala	Asp	Pro	Leu	Pro	Asn	Asn	Ala	Val	Ile	His	Asn	Ser	Trp
				395					400					405
Ile	Asp	Pro	Lys	Arg	Asn	Lys	Lys	Ile	Thr	Phe	Glu	Asp	Ser	Glu
				410					415					420
Ile	Arg	Glu	Lys	Cys	Leu	Val	Pro	Gln	Val	Val	Thr	Asp		
				425					430					

<210> 2
 <211> 2238
 <212> DNA
 <213> Homo sapiens

<220> -
 <223> 282414

<400> 2
 tgaccctaataa aaagcatgta gctgaagtat tggagagaaa acgaaagaat tctccaaga 60
 catgaaataa aacacagcta cttcactgtt gtcagggaaa aaaaccaact gtcctcaaaag 120
 aatgtgtttt tctcccatc tggaaatcaa catgcagtct gaatctaaca ttacagtgcg 180
 agatgacatt gatgacatca acaccaatat gtaccaacca ctatcatatc cggttaagctt 240
 tcaagtgtct ctcaccgat ttcttatgtt agaaattttt tttggacttg gcagcaaacct 300
 cactgtattg gtactttact gcatgaaatc caacttaatc aactctgtca gtaacattat 360
 tacaatgaat cttcatgtac ttgatgtaat aatttgtgtg ggatgtattc ctctaactat 420
 agttatcctt ctgctttcac tggagagtaa cactgctctc atttgctgtt tccatgaggc 480
 ttgtgtatct tttgcaagtg tctcaacagc aatcaacggt tttgctatca ctttggacag 540
 atatgacatc tctgtaaaac ctgcaaaccg aattctgaca atgggcagag ctgtaatgtt 600
 aatgatatacc atttgattt tttctttttt ctctttcctg attcctttta ttgaggtaaa 660
 ttttttcagt cttcaaagtg gaaataacctg ggaaaacaag acacttttat gtgtcagtac 720
 aaatgaatac tacactgaac tgggaatgta ttatcacctg ttagtacaga tcccaatatt 780
 ctttttcact gttgtagtaa tgtaaatcac atacaccaa atacttcagg ctcttaatat 840
 tcgaataggc acaagatttt caacagggca gaagaagaaa gcaagaaaga aaaagacaat 900
 ttctctaacc acacaacatg aggctacaga catgtcaca agcagtgggt ggagaaatgt 960
 agtctttggt gtaagaactt cagtttctgt aataattgcc ctccggcgag ctgtgaaacg 1020
 acaccgtgaa cgacgagaaa gactaaagag agtcttcagg atgtctttat tgattatttc 1080
 tacatttctt ctctgctgga caccaatttc tgttttaaat accaccattt tatgtttagg 1140
 cccaagtgac ctttttagtaa aattaagatt gtgtttttta gtcatggctt atggaacaac 1200
 tatatttcac cctctattat atgcattcac tagacaaaaa tttcaaaagg tcttgaaaag 1260
 taaaatgaaa aagcaggttg tttctatagt agaagctgat ccctgccta ataagtctgt 1320
 aatacacaac tcttgatag atcctaaaag aaacaaaaaa attacctttg aagatagtga 1380
 aataagagaa aaatgttttag tgcctcaggt tgtcacagac tagagaaaag tctcagtttc 1440

```

accaaatcca cattcaaag agtttttaaat ttaaattgta aaaactgata ttactgcaa 1500
atataagaaa aatatttttaa gtattgggta tgttgtaa atttcaatgtg aatgtcaatt 1560
agatagggtca tatatatcca atttcttcat tacttaattgt atttgttgca tggcagtttg 1620
ttaaagtact atcatgtgta tattttgtca atattatgtc caacagaaaa tattcatgta 1680
agtcataattt ttttaaggaat aaatacatag ccttaaaaca gtgtataact ttaaaatgta 1740
actgacatag gtatccttgc tttatttttt aagttaaaat gcattgtttc taagccacaa 1800
actacagata tatttagatt acaactggag tagcatttta atctaaaaac caaaattatg 1860
ggctcaaaac aatccagtat tttccatacc actatgctat gtttcctggg atagtgtatt 1920
tgctatattt gatgcatcac aaataattaa gtacgtatga agctttattc ttttaaattg 1980
aaaaaatcat agaattttatc aaaatttttaa aattaatgaa ccaaaaaaac ctctgtatac 2040

```

```

acacccaaat agagaaactt taaaattcat gcttactagg aaaaaaaga ttgattttct 2100
aagttcaagg acagtatgcc tataatatac aaatgaaatg aaactaaagg gaaggaagaa 2160
tactaaaaca ccagcctctt tcttccttcc tcactttgct taagtctaag ccaaatgctc 2220
tggattaata tactcaca 2238

```

<210> 3
 <211> 430
 <212> PRT
 <213> Homo sapiens

<220> -
 <223> g544724

<400> 3

Met	Asp	Val	Val	Asp	Ser	Leu	Phe	Val	Asn	Gly	Ser	Asn	Ile	Thr
1				5					10					15
Ser	Ala	Cys	Glu	Leu	Gly	Phe	Glu	Asn	Glu	Thr	Leu	Phe	Cys	Leu
			20						25					30
Asp	Arg	Pro	Arg	Pro	Ser	Lys	Glu	Trp	Gln	Pro	Ala	Val	Gln	Ile
			35						40					45
Leu	Leu	Tyr	Ser	Leu	Ile	Phe	Leu	Leu	Ser	Val	Leu	Gly	Asn	Thr
			50						55					60
Leu	Val	Ile	Thr	Val	Leu	Ile	Arg	Asn	Lys	Arg	Met	Arg	Thr	Val
			65						70					75
Thr	Asn	Ile	Phe	Leu	Leu	Ser	Leu	Ala	Val	Ser	Asp	Leu	Met	Leu
			80						85					90
Cys	Leu	Phe	Cys	Met	Pro	Phe	Asn	Leu	Ile	Pro	Ser	Leu	Leu	Lys
			95						100					105
Asp	Phe	Ile	Phe	Gly	Ser	Ala	Val	Cys	Lys	Thr	Thr	Thr	Tyr	Phe
			110						115					120
Met	Gly	Thr	Ser	Val	Ser	Val	Ser	Thr	Phe	Asn	Leu	Val	Ala	Ile
			125						130					135
Ser	Leu	Glu	Arg	Tyr	Gly	Ala	Ile	Cys	Lys	Pro	Leu	Gln	Ser	Arg
			140						145					150
Val	Trp	Gln	Thr	Lys	Ser	His	Ala	Leu	Lys	Val	Ile	Ala	Ala	Thr
			155						160					165
Trp	Cys	Leu	Ser	Phe	Thr	Ile	Met	Thr	Pro	Tyr	Pro	Ile	Tyr	Ser
			170						175					180
Asn	Leu	Val	Pro	Phe	Thr	Lys	Asn	Asn	Asn	Gln	Thr	Gly	Asn	Met
			185						190					195
Cys	Arg	Phe	Leu	Leu	Pro	Asn	Asp	Val	Met	Gln	Gln	Thr	Trp	His
			200						205					210
Thr	Phe	Leu	Leu	Leu	Ile	Leu	Phe	Leu	Ile	Pro	Gly	Ile	Val	Met
			215						220					225
Met	Val	Ala	Tyr	Gly	Leu	Ile	Ser	Leu	Glu	Leu	Tyr	Gln	Gly	Ile
			230						235					240
Lys	Phe	Asp	Ala	Ile	Gln	Lys	Lys	Ser	Ala	Lys	Glu	Arg	Lys	Thr
			245						250					255

```

Ser Thr Gly Ser Ser Gly Pro Met Glu Asp Ser Asp Gly Cys Tyr
      260      265      270
Leu Gln Lys Ser Arg His Pro Arg Lys Leu Glu Leu Arg Gln Leu
      275      280      285
Ser Pro Ser Ser Ser Gly Ser Asn Arg Ile Asn Arg Ile Arg Ser
      290      295      300
Ser Ser Ser Thr Ala Asn Leu Met Ala Lys Lys Arg Val Ile Arg
      305      310      315
Met Leu Ile Val Ile Val Val Leu Phe Phe Leu Cys Trp Met Pro
      320      325      330
Ile Phe Ser Ala Asn Ala Trp Arg Ala Tyr Asp Thr Val Ser Ala
      335      340      345
Glu Arg His Leu Ser Gly Thr Pro Ile Ser Phe Ile Leu Leu Leu
      350      355      360
Ser Tyr Thr Ser Ser Cys Val Asn Pro Ile Ile Tyr Cys Phe Met
      365      370      375
Asn Lys Arg Phe Arg Leu Gly Phe Met Ala Thr Phe Pro Cys Cys
      380      385      390

```

```

Pro Asn Pro Gly Thr Pro Gly Val Arg Gly Glu Met Gly Glu Glu
      395      400      405
Glu Glu Gly Arg Thr Thr Gly Ala Ser Leu Ser Arg Tyr Ser Tyr
      410      415      420
Ser His Met Ser Thr Ser Ala Pro Pro Pro
      425      430

```

<210> 4
 <211> 371
 <212> PRT
 <213> Homo sapiens

<220> -
 <223> g1378004

```

<400> 4
Met Glu Val Leu Thr Asn Gln Pro Thr Pro Asn Lys Thr Ser Gly
  1      5      10      15
Lys Ser Asn Asn Ser Ala Phe Phe Tyr Phe Glu Ser Cys Gln Pro
      20      25      30
Pro Phe Leu Ala Ile Leu Leu Leu Leu Ile Ala Tyr Thr Val Ile
      35      40      45
Leu Ile Met Gly Ile Phe Gly Asn Leu Ser Leu Ile Ile Ile Ile
      50      55      60
Phe Lys Lys Gln Arg Glu Ala Gln Asn Val Thr Asn Ile Leu Ile
      65      70      75
Ala Asn Leu Ser Leu Ser Asp Ile Leu Val Cys Val Met Cys Ile
      80      85      90
Pro Phe Thr Val Ile Tyr Thr Leu Met Asp His Trp Val Phe Gly
      95      100      105
Asn Thr Met Cys Lys Leu Thr Ser Tyr Val Gln Ser Val Ser Val
      110      115      120
Ser Val Ser Ile Phe Ser Leu Val Leu Ile Ala Ile Glu Arg Tyr
      125      130      135
Gln Leu Ile Val Asn Pro Arg Gly Trp Lys Pro Arg Val Ala His
      140      145      150
Ala Tyr Trp Gly Ile Ile Leu Ile Trp Leu Ile Ser Leu Thr Leu
      155      160      165

```


Ser	Ile	Pro	Leu	Phe	Leu	Ser	Tyr	His	Leu	Thr	Asn	Glu	Pro	Phe	170	175	180
His	Asn	Leu	Ser	Leu	Pro	Thr	Asp	Ile	Tyr	Thr	His	Gln	Val	Ala	185	190	195
Cys	Val	Glu	Ile	Trp	Pro	Ser	Lys	Leu	Asn	Gln	Leu	Leu	Phe	Ser	200	205	210
Thr	Ser	Leu	Phe	Met	Leu	Gln	Tyr	Phe	Val	Pro	Leu	Gly	Phe	Ile	215	220	225
Leu	Ile	Cys	Tyr	Leu	Lys	Ile	Val	Leu	Cys	Leu	Arg	Lys	Arg	Thr	230	235	240
Arg	Gln	Val	Asp	Arg	Arg	Lys	Glu	Asn	Lys	Ser	Arg	Leu	Asn	Glu	245	250	255
Asn	Lys	Arg	Val	Asn	Val	Met	Leu	Ile	Ser	Ile	Val	Val	Thr	Phe	260	265	270
Gly	Ala	Cys	Trp	Leu	Pro	Leu	Asn	Ile	Phe	Asn	Val	Ile	Phe	Asp	275	280	285
Trp	Tyr	His	Glu	Met	Leu	Met	Ser	Cys	His	His	Asp	Leu	Val	Phe	290	295	300
Val	Val	Cys	His	Leu	Ile	Ala	Met	Val	Ser	Thr	Cys	Ile	Asn	Pro	305	310	315
Leu	Phe	Tyr	Gly	Phe	Leu	Asn	Lys	Asn	Phe	Gln	Lys	Asp	Leu	Met	320	325	330
Met	Leu	Ile	His	His	Cys	Trp	Cys	Gly	Glu	Pro	Gln	Glu	Ser	Tyr	335	340	345
Glu	Asn	Ile	Ala	Met	Ser	Thr	Met	His	Thr	Asp	Glu	Ser	Lys	Gly	350	355	360
Ser	Leu	Lys	Leu	Ala	His	Ile	Pro	Thr	Gly	Ile					365	370	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/17690

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/70 C12N1/21 C07K14/705 C07K16/28
C12Q1/68 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	O'DOWD B F ET AL: "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, vol. 187, no. 1, 10 March 1997, page 75-81 XP004056114 see the whole document -----	1-20

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 December 1998

Date of mailing of the international search report

15/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gall, I

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 17690

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Please see Further Information sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark: Although claims 16-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

The agonists and antagonists mentioned in claims 14 and 15 are not sufficiently disclosed to allow for a meaningful and complete search.